Medicare Enrolled
Dr. Patrick Frey, MD
Urology Physician · Grapevine, TX
Practice pattern: Clinical Cardiology
— Primarily office-based clinical cardiology
Low-engagement
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Frey from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Frey?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Frey
Dr. Patrick Frey is an urology physician in Grapevine, TX, with 20 years of NPI registration. Based on federal Medicare data, Dr. Frey performed 3,349 Medicare services across 2,354 unique beneficiaries.
Between the years covered by Open Payments, Dr. Frey received a total of $2,917 from 42 pharmaceutical and/or device companies across 139 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in urology physician. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Frey is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 20 years in practice
▲ Top 36% volume in TX
$2,917 industry payments
Medicare Practice Summary
Medicare Utilization ↗3,349
Medicare services
Top 36% in TX for urology physician
2,354
Unique beneficiaries
$94
Avg. Medicare payment
Medicare patients only (65+ / disabled) · Not a quality rating · How to read this →
~167 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
640 | $64 | $183 |
| Blood draw (venipuncture) Insertion of a needle into a vein to collect a blood sample. |
472 | $8 | $16 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
354 | $88 | $259 |
| PSA test (prostate cancer screening) | 315 | $18 | $37 |
| Automated urinalysis An automated laboratory test performed on a urine sample to analyze its chemical and physical properties. The procedure uses machinery to detect various substances and cells within the urine. |
274 | $2 | $5 |
| Urine culture, bacterial identification A laboratory test that grows and identifies bacteria from a urine sample to detect infections. |
132 | $8 | $16 |
| Urine culture, bacterial colony count A laboratory test that measures the number of bacteria growing in a urine sample to help identify infections. |
113 | $8 | $16 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 100 | $133 | $378 |
| Cystourethroscopy A diagnostic exam of the bladder and urethra using an endoscope to visually inspect the urinary tract. |
98 | $187 | $494 |
| Total testosterone level test A blood test that measures the total amount of testosterone in your body. This hormone is important for various bodily functions in both men and women. |
92 | $25 | $52 |
| New patient office visit (45-59 min) An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter. |
87 | $121 | $336 |
| Bacterial culture, aerobic A laboratory test that grows and identifies bacteria capable of surviving in oxygen. The results help determine the presence of specific aerobic microorganisms. |
78 | $8 | $16 |
| New patient office visit (30-44 min) An initial office visit for a new patient lasting between 30 and 44 minutes. This code is used when the total time spent on the date of the encounter falls within this range. |
78 | $76 | $226 |
| Antibiotic sensitivity test A laboratory test that determines which antibiotics, antifungals, or antivirals are effective against a specific microorganism using microdilution or agar dilution methods. |
76 | $8 | $17 |
| Comprehensive metabolic blood panel A blood test that measures a group of chemicals, including glucose, electrolytes, and kidney and liver function markers. |
66 | $10 | $21 |
| Injection of biodegradable material next to prostate A procedure involving the injection of a biodegradable substance into the tissue surrounding the prostate gland. |
45 | $2,293 | $6,009 |
| Hormone pellet insertion under the skin A small hormone pellet is placed just beneath the skin to release medication slowly over time. |
44 | $76 | $191 |
| Unclassified drug A medication that does not fit into standard HCPCS or CPT classification categories. |
40 | $1,260 | $2,992 |
| Prostate gland biopsy A procedure to remove small samples of tissue from the prostate gland for laboratory examination. |
37 | $188 | $491 |
| Transrectal ultrasound of the pelvis An ultrasound imaging procedure where a probe is inserted into the rectum to visualize pelvic structures. |
37 | $106 | $282 |
| Injection, garamycin, gentamicin, up to 80 mg | 29 | $2 | $6 |
| Free PSA test A blood test that measures the amount of unbound prostate-specific antigen in the blood. |
28 | $18 | $37 |
| Total estradiol level test A blood test that measures the total amount of estradiol, a form of estrogen, in the body. |
24 | $27 | $56 |
| Initial hospital admission, moderate complexity Initial hospital inpatient or observation care for a new patient involving moderate-level medical decision making, with at least 55 minutes total time on the date of the encounter. |
23 | $104 | $262 |
| Bladder ultrasound after voiding An ultrasound scan performed after urination to measure the amount of urine remaining in the bladder. |
22 | $8 | $22 |
| Subcutaneous or intramuscular chemotherapy injection This procedure involves administering anti-cancer hormonal medication through an injection into the tissue under the skin or into a muscle. |
21 | $27 | $70 |
| Bladder irrigation and/or instillation This procedure involves flushing the bladder with fluid to clear it or introducing medication directly into the bladder. |
13 | $61 | $156 |
| Ureteral stone crushing with stent insertion An endoscope is used to break up a stone in the ureter, followed by the placement of a stent to keep the ureter open. |
11 | $326 | $816 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
0.3% high complexity
5.7% medium
94.0% routine
Industry Payment Transparency
Open Payments through 2024 ↗$2,917
Total received (2018-2024)
Avg $417/year across 7 years
Bottom 48% in TX for urology physician
42
Companies
139
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$2,865 (98.2%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$52 (1.8%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$587
2023
$559
2022
$469
2021
$305
2020
$184
2019
$718
2018
$94
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
Boston Scientific Corporation
$509
Antares Pharma, Inc.
$317
PFIZER INC.
$288
Astellas Pharma US Inc
$214
Sumitomo Pharma America, Inc.
$129
Dendreon Pharmaceuticals LLC
$126
PROCEPT BioRobotics Corporation
$122
Innovation Technologies Inc
$95
Ferring Pharmaceuticals Inc.
$76
ABBVIE INC.
$76
BOSTON SCIENTIFIC CORPORATION
$69
C. R. Bard, Inc. & Subsidiaries
$63
Axonics, Inc.
$56
UROGEN PHARMA, INC.
$52
Progenics Pharmaceuticals, Inc.
$46
Supernus Pharmaceuticals, Inc.
$42
Sun Pharmaceutical Industries Inc.
$40
Blue Earth Diagnostics Limited
$39
Caldera Medical, Inc
$37
Olympus America Inc.
$35
Endo Pharmaceuticals Inc.
$34
Pacira Pharmaceuticals Incorporated
$33
Merck Sharp & Dohme Corporation
$32
Allergan Inc.
$32
Janssen Biotech, Inc.
$27
Laborie Medical Technologies Corp.
$27
Tempus AI, Inc
$25
Eisai Inc.
$23
UroGen Pharma, Inc.
$21
Merck Sharp & Dohme LLC
$21
Clovis Oncology, Inc.
$20
AstraZeneca Pharmaceuticals LP
$19
Levita Magnetics International Corp
$19
AbbVie, Inc.
$19
Cook Medical LLC
$18
ACCORD HEALTHCARE, INC.
$18
Retrophin, Inc.
$18
Amgen Inc.
$16
Verity Pharmaceuticals Inc.
$16
Accord Healthcare, Inc.
$15
Coloplast Corp
$15
COLOPLAST CORP
$13
Top 3 companies account for 38.2% of total payments
Associated products mentioned in payments ›
(815) Thiola · ADSTILADRIN · ADVANCE · AQUABEAM ROBOTIC SYSTEM · AQUABEAM SYSTEM · Axonics · Axumin · BOTOX · BOTOX THERAPEUTIC · CAMCEVI · Desara · ERLEADA · Erleada · Exparel · Flexiva · GENERAL BPH · GENERAL FEMALE SUI · GENERAL ONCOLOGY · GENERAL - KIDNEY STONE DISEASE · IRRISEPT · JELMYTO · KEYTRUDA · LITHOVUE · LYNPARZA · Lenvima · LithoVue · Lupron Depot · MYRBETRIQ · Magnetic Surgery · Moses 550 D\F\L · Myrbetriq · NICORE · NOCDURNA · ORGOVYX · OTREXUP · Olympus Stents · Otrexup · PROVENGE · PYLARIFY · RESONANCE · REZUM · ReTrace · Rezum Generator · Rubraca · SOLYX · SPACEOAR VUE · SpaceOAR VUE System - 10mL · SpeediCath · TLANDO · TOVIAZ · Trelstar · XGEVA · XIAFLEX · XTANDI · XYOSTED · Xtandi · YONSA · iTIND System · rezum Generator
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Most payments (98%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.
Equivalent to $87 per 100 Medicare services performed
Geographic Context
Urology physicians within 10 mi
180
Per 100K population
8.4
County median income
$81,905
Nearest hospital
BAYLOR SCOTT & WHITE MEDICAL CENTER GRAPEVINE
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →
Summary
Dr. Frey is a clinical cardiology specialist, with moderate Medicare volume, with low-engagement industry engagement, with 20 years of NPI registration.
This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →
Frequently Asked Questions
Is Dr. Frey experienced with office visit, established patient (20-29 min)?
Based on Medicare claims data, Dr. Frey performed 640 office visit, established patient (20-29 min) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Frey receive payments from pharmaceutical companies?
Yes. Dr. Frey received a total of $2,917 from 42 companies across 139 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Frey's costs compare to other urology physicians in Grapevine?
Dr. Frey's average Medicare payment per service is $94. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Frey) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Urology Physicians in Grapevine
Browse urology physicians in Grapevine ranked by procedure volume and transparency data.
Highest volume
Top Urology Physicians in TX
Urology physicians ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Urology Physicians in TX
Which TX urology physicians receive the most from drug and device companies.
By company
Boston Scientific Corporation Payments to Doctors
See all physicians who received payments from Boston Scientific Corporation.
By company
Antares Pharma, Inc. Payments to Doctors
See all physicians who received payments from Antares Pharma, Inc.
By company
PFIZER INC. Payments to Doctors
See all physicians who received payments from PFIZER INC.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology